I tried to warn last December (see below) that it was dangerous...

I tried to warn last December (see below) that it was dangerous to use historical data as a comparator. When no one contested that proposition, I sold all my shares.

I truly regret that long-term shareholders have suffered a painful lesson.


"Cane,
I am a Kazia shareholder, so it gives me no pleasure to say that in my opinion, the reason for the selling can be found in the following 2020 report:

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis (nih.gov)

"The median OS for patients with unmethylated GBM treated with RT/TMZ pooled from 5 phase III studies (N = 655) was 14.11 months"

Historical median survival for TMZ of 12.7 months referred to data from 2005, 16 years ago. We should have expected that improvement in patient care over that period would lead to better responses.

I suspect that some investors worked this out and formed the view that the difference between 15.7 months and 14.11 months was not clinically significant.

I will actually be happy to be proven wrong, so fire away!"